Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation.

Virchows Archiv : an international journal of pathology - 1 Jun 2007

Preto Ana, Moutinho Cátia, Velho Sérgia, Oliveira Carla, Rebocho Ana Paula, Figueiredo Joana, Soares Paula, Lopes José Manuel, Seruca Raquel

Abstract excerpt

c-KIT is a tyrosine kinase receptor found to be overexpressed in several tumours, namely, GISTs, breast, lung, prostate, ovarian and colorectal carcinomas (CRC). We aimed at determining the frequency of c-KIT expression and mutations in a series of 109 CRC cases (73 primary tumours and 36 lymph node metastases) characterised for KRAS and BRAF mutations. We also aimed at analysing the cellular effects of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrimidines

Share to ras Proteins

Source

Identifiers

PMID: 17487504
DOI: 10.1007/s00428-007-0420-9

Genes

KIT
BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation.PMID 17487504Read ↗

C-KIT signaling in cancer treatment.Semantic proximity Read ↗

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.Semantic proximity Read ↗

Targeting c-Kit mutations: basic science to novel therapies.Semantic proximity Read ↗

Therapeutic targeting of c-KIT in cancer.Semantic proximity Read ↗

Clinical management of gastrointestinal stromal tumors: before and after STI-571.Semantic proximity Read ↗

c-Kit Receptors as a Therapeutic Target in Cancer: Current InsightsSemantic proximity Read ↗

KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.Semantic proximity Read ↗

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.Semantic proximity Read ↗

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.Semantic proximity Read ↗

Predicting the antitumor effects of STI571 by analysis of c-kit gene mutations in gastrointestinal stromal tumors of the stomach: Report of a case.Semantic proximity Read ↗

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitorsSemantic proximity Read ↗

The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.